Goserelin acetate

Drug Overview

Goserelin acetate (commonly known by its brand name Zoladex) is a synthetic decapeptide analogue of the naturally occurring gonadotropin-releasing hormone (GnRH). It belongs to a class of medications called GnRH agonists (or LHRH agonists). Goserelin is primarily used as a hormone therapy to treat various hormone-sensitive cancers and benign gynecological conditions by significantly reducing the production of sex hormones (testosterone in men and estrogen in women).

• Generic Name: Goserelin acetate.
• Brand Name: Zoladex.
• Drug Class: GnRH (Gonadotropin-Releasing Hormone) Agonist.
• Target: Pituitary GnRH receptors.
• Route of Administration: Subcutaneous (SC) implant (depot).
• FDA Approval Status: Approved for prostate cancer, advanced breast cancer (pre- and perimenopausal), endometriosis, and endometrial thinning.

What Is It and How Does It Work? (Mechanism of Action)

Goserelin acts as a powerful modulator of the hypothalamic-pituitary-gonadal axis. Its mechanism is biphasic, involving an initial stimulation followed by a long-term suppression of hormone production.

Biphasic Mechanism

1. Initial Phase (Flare): Upon administration, goserelin acts as an agonist, stimulating the GnRH receptors in the pituitary gland. This causes a temporary surge in the release of Luteinizing Hormone (LH) and Follicle-Stimulating Hormone (FSH), which initially increases testosterone levels in men and estrogen levels in women.
2. Sustained Phase (Downregulation): With continuous exposure, goserelin causes the GnRH receptors in the pituitary to become desensitized and downregulated. This leads to a profound drop in LH and FSH secretion. Consequently, testosterone levels in men fall to “castrate levels” (typically within 2–4 weeks), and estrogen levels in women fall to postmenopausal levels.

By lowering these hormones, goserelin starves hormone-sensitive cancer cells (such as those in prostate or breast cancer) of the “fuel” they need to grow and multiply.

FDA-Approved Clinical Indications

As of 2026, goserelin acetate remains a standard of care for several indications:

• Prostate Cancer: * Palliative treatment of advanced carcinoma of the prostate.
  • In combination with radiotherapy and an antiandrogen (like flutamide) for the management of locally confined (Stage T2b-T4) prostate cancer.
• Breast Cancer: * Palliative treatment of advanced (Stage IV) breast cancer in pre- and perimenopausal women.
  • Off-label/Standard use: Often used as Ovarian Function Suppression (OFS) in the adjuvant treatment of early-stage hormone receptor-positive (HR+) breast cancer, frequently in combination with tamoxifen or aromatase inhibitors.
• Endometriosis: For the management of symptoms, including pain relief and reduction of endometriotic lesions.
• Endometrial Thinning: Used prior to endometrial ablation for dysfunctional uterine bleeding to thin the lining of the uterus.

Dosage and Administration Protocols

Goserelin is unique because it is administered as a biodegradable subcutaneous implant (a small “pellet”) that releases the medication slowly over time.

Clinical Efficacy and Research Results

Clinical trials have established goserelin as a highly effective hormonal blockade:

• Prostate Cancer: In advanced disease, goserelin is equivalent to surgical castration (orchiectomy) in suppressing testosterone and controlling tumor growth.
• Breast Cancer: The ABCSG-12 and SOFT/TEXT trials demonstrated that adding goserelin for ovarian suppression significantly reduces the risk of recurrence in premenopausal women with high-risk HR+ breast cancer when added to other endocrine therapies.
• 2026 Update: Ongoing research (e.g., NCT07460752) is evaluating alternative injection sites (such as the gluteal region) to improve patient comfort while maintaining effective hormone suppression.

Safety Profile and Side Effects

The side effects of goserelin are largely a direct result of the profound hormonal suppression it induces (chemical menopause or andropause).

Common Side Effects (>20%)

• Hot Flushes and Sweating: The most frequently reported symptom in both men and women.
• Sexual Dysfunction: Decreased libido, erectile dysfunction (men), and vaginal dryness (women).
• Mood Changes: Emotional lability, depression, and anxiety.
• Injection Site Reactions: Mild bruising, pain, or redness.

Serious or Long-Term Risks

• Bone Density Loss (Osteoporosis): Long-term use can lead to weakened bones and increased fracture risk. Supplementation with Vitamin D and calcium is often recommended.
• Tumor Flare: In the first 2 weeks, the initial testosterone surge can temporarily worsen symptoms (e.g., bone pain or urinary blockage in prostate cancer). Men are often prescribed an antiandrogen for the first month to prevent this.
• Cardiovascular Risks: Increased risk of myocardial infarction, stroke, or sudden cardiac death has been noted in men receiving GnRH agonists.
• Metabolic Changes: Weight gain and an increased risk of developing diabetes (hyperglycemia).

Research Areas

In Stem Cell and Regenerative Medicine, goserelin is being investigated for its potential role in Fertility Preservation. During chemotherapy, the toxic drugs often destroy rapidly dividing cells in the ovaries, leading to permanent infertility. Research suggests that by using goserelin to “shut down” or “quiet” the ovaries (putting them in a dormant state) during chemotherapy, the ovarian stem cells and follicles may be protected from damage, potentially allowing for the return of natural fertility after cancer treatment is completed.

Patient Management and Practical Recommendations

Pre-treatment Tests

• Pregnancy Test: Must be confirmed negative in women before starting (unless used for advanced breast cancer).
• Bone Density (DEXA) Scan: To establish a baseline for bone health.
• Blood Glucose/HbA1c: To monitor for metabolic changes or diabetes.

Precautions

• Injection Caution: Care must be taken to avoid the inferior epigastric artery during abdominal injection, particularly in patients with a low BMI or those on anticoagulants.
• Birth Control: Use non-hormonal birth control (e.g., condoms) during treatment and for at least 12 weeks after the last implant.

“Do’s and Don’ts”

• DO report sudden bone pain or difficulty urinating in the first few weeks (potential tumor flare).
• DO engage in weight-bearing exercise to help maintain bone density.
• DON’T miss your scheduled appointments; hormonal levels can recover quickly if the depot is not replaced on time.
• DON’T ignore symptoms of severe depression or suicidal thoughts.

Legal Disclaimer

The information provided is for educational and informational purposes only and does not constitute medical advice. Goserelin acetate is a prescription medication that must be administered under the supervision of a healthcare professional. Always consult with your oncologist or specialist regarding your specific diagnosis, treatment plan, and any side effects you may experience.